SOURCE: Cellceutix

November 28, 2011 06:30 ET

Dr. Paul Marks Joins Cellceutix Scientific Advisory Board; Cellceutix Files Worldwide Patents to Protect Kevetrin™

BEVERLY, MA--(Marketwire - Nov 28, 2011) - Cellceutix Corporation (OTCBB: CTIX) ("the Company"), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat unmet medical conditions, is pleased to report that Dr. Paul Marks has joined the Cellceutix Scientific Advisory Board.

Dr. Marks served as President and Chief Executive Officer of Memorial Sloan-Kettering Cancer Center ("MSKCC") from 1980 to 1999 where he helped to establish the high standards for research and patient care that MSKCC is world renowned for. He remains a vital part of MSKCC as President Emeritus and Member of the Sloan-Kettering Institute. Dr. Marks' research in cell biology and cancer genetics has made major contributions toward a new approach to cancer treatment and prevention, through the development of new and more potent chemotherapy and chemoprevention agents. He also helped establish the highest standards for research and patient care at MSKCC and has provided leadership in the national and international medical science community.

Dr. Marks received his AB and MD degrees from Columbia University and postdoctoral training at the National Institutes of Health and the Pasteur Institute. Prior to his tenure at MSKCC, he was Professor of Human Genetics and Frode Jensen Professor of Medicine (1968-1980), Dean of the Faculty of Medicine (1970-1973), and Vice President for Health Sciences and Director of the Comprehensive Cancer Center (1973-1980) at Columbia University.

Dr. Marks is a member of the National Academy of Sciences and the Institute of Medicine and is a Fellow at the American Academy of Arts and Sciences. He has been a recipient of numerous honors. He has published more than 350 scientific articles in various scholarly journals. (

Additionally, Cellceutix has now filed foreign patent applications relating to pharmaceutical compositions comprising its anti-cancer compound Kevetrin™. These applications are based on the earlier International Application filed under the Patent Cooperation Treaty in 2009.

The applications were filed under the direction of John Richards of the preeminent international intellectual property law firm Ladas & Parry. Mr. Richards is one of the leading worldwide experts on international pharmaceutical and chemical patents, having represented numerous large corporations on cases of major commercial significance.

"We are extremely pleased to add Dr. Marks to our team," commented Cellceutix Chief Scientific Officer Dr. Krishna Menon. "We have assembled a world-class advisory board with Dr. Emil Frei, Dr. Samuel Danishefsky, Dr. Paul Ginsburg and now Dr. Paul Marks. Going forward with Kevetrin™ in clinical trials, as well as other drugs in our pipeline, their experience and knowledge will play a key role in our success. I wish to add that I have never been as excited about a cancer compound as I am now with Kevetrin. Everything is coming together very nicely. It is indeed a very exciting time for Cellceutix and its shareholders."

About Cellceutix

Cellceutix Corporation is a preclinical cancer, anti-inflammatory and autism drug developer. More information is available on the Cellceutix web site at

Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Factors that may impact Cellceutix's success are more fully disclosed in Cellceutix's most recent public filings with the U.S. Securities and Exchange Commission.

Contact Information

  • Contact:
    Cellceutix Corp.
    Leo Ehrlich
    (978) 236-8717
    Email Contact